Salubris(SZ:002294) Xin Lang Cai Jing·2025-09-05 06:20Group 1 - The core viewpoint of the news is that Shenzhen Xinlitai Pharmaceutical Co., Ltd. has seen a stock price increase of 5.11%, reaching 57.21 CNY per share, with a total market capitalization of 63.779 billion CNY [1] - The company was established on November 3, 1998, and went public on September 10, 2009. Its main business involves the research, production, and sales of pharmaceuticals and medical devices [1] - The revenue composition of the company is as follows: formulations account for 81.69%, medical devices 8.54%, raw materials 7.17%, and others 2.59% [1] Group 2 - From the perspective of fund holdings, one fund under Yinhua Fund has a significant position in Xinlitai, holding 5.2574 million shares, which constitutes 2.63% of the fund's net value, ranking it as the eighth largest holding [2] - The fund, named Innovation Medicine (159992), has a total scale of 9.473 billion CNY and has achieved a year-to-date return of 37.91%, ranking 416 out of 4222 in its category [2] - The fund has a one-year return of 56.73%, ranking 1242 out of 3795, but has experienced a loss of 3.98% since its inception [2] Group 3 - The fund managers of Innovation Medicine are Ma Jun and Wang Shuai, with Ma having a tenure of 13 years and 5 days, managing assets totaling 33.304 billion CNY, and achieving a best return of 144.61% during his tenure [3] - Wang Shuai has a tenure of 6 years and 72 days, managing assets of 20.936 billion CNY, with a best return of 76.27% during his tenure [3]